Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

However, factors like market crashes or difficult regulations could invalidate this bullish theory. To support its web3 ecosystem for developing decentralized applications, The Graph Network ...

A PyTorch-based package built for graph signal processing(especially critical-sampling graph wavelet analysis).